+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

DiaSorin SpA (DIA) - Product Pipeline Analysis, 2022 Update

  • PDF Icon

    Company Profile

  • 131 Pages
  • July 2022
  • GlobalData
  • Diasorin
  • ID: 5637106
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

DiaSorin SpA (DiaSorin) is a medical diagnostics company that is engaged in the development, manufacturwing, and marketing of in vitro diagnostics reagent kits and systems. The company develops reagent kits based on Enzyme Linked Immunosorbent Assays (ELISA) and Chemiluminescence (CLIA) techniques, to enable automatic diagnostic investigation. The company’s immunodiagnostic and molecular diagnostics products find application in the diagnosis of infectious diseases, bone and mineral disorders, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmune disorders, and neurological and cardiac diseases, among others. DiaSorin markets its products through direct sales force and distributors. It has operations in North America, South America, South Africa, Europe, the Middle East, Africa and Asia. DiaSorin is headquartered in Saluggia, Piemonte, Italy.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company DiaSorin SpA
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • DiaSorin SpA Company Overview
  • DiaSorin SpA Company Snapshot
  • DiaSorin SpA Pipeline Products and Ongoing Clinical Trials Overview
  • DiaSorin SpA - Pipeline Analysis Overview
  • Business Description
  • DiaSorin SpA - Key Facts
  • DiaSorin SpA - Majo

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Thermo Fisher Scientific Inc
  • Sysmex Corp
  • Siemens Healthineers AG
  • Roche Diagnostics International Ltd
  • Quidel Corp
  • Qiagen NV
  • Ortho Clinical Diagnostics Holdings Plc
  • Danaher Corp
  • Bio-Rad Laboratories Inc
  • bioMerieux SA
  • Becton Dickinson and Co